Texas Endovascular has exited in a private equity deal. Photo courtesy of Getty Images

A Houston-based startup specializing in minimally invasive vascular procedures has made an exit.

Fulcrum Equity Partners, based in Atlanta, has announced the acquisition of Texas Endovascular Associates, a specialty physician practice across five locations in the greater Houston area. The terms of the deal were not disclosed.

“We are excited to partner with the Texas Endovascular team to continue growing the impressive platform they have already built,” says Tom Greer of Fulcrum Equity Partners in a news release. “The company has created a differentiated service model and is well positioned to continue its growth in Texas. We look forward to building on this strong presence in the state as well as pursuing strategic acquisitions as we expand its geographical footprint.”

Fulcrum manages over $600 million in assets and provides expansion capital to rapidly growing companies within health care — including IT, B2B software, and more.

The new funding will spur Texas Endovascular's growth into its next phase of business.

“We knew that finding the right equity partner was critical to our long-term growth prospects,” said Sean Mullen, CEO of Texas Endovascular. “After an exhaustive search and after meeting with multiple prospective PE firms, we chose Fulcrum because of their healthcare experience, collaborative approach, and impressive track record. We are excited to enter this new chapter in our company’s life with Fulcrum as our partner."

The two entities collaborated with Founders Advisors LLC, a merger, acquisition, and strategic advisory firm serving middle-market companies.

“Working with the founders of the practice, Drs. Fox and Hardee, as well as the CEO, Sean Mullen, was a pleasure. The entire team at Texas Endovascular acted as a cohesive unit and persevered to find the right partner in Fulcrum," says Michael White, managing director at Founders Advisors. "We are grateful for the opportunity to be a part of this process and we are looking forward to the future of Texas Endovascular in partnership with Fulcrum”.

Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

TMC launches new biotech partnership with Republic of Korea

international collaboration

Houston's Texas Medical Center has launched its new TMC Republic of Korea BioBridge.

The new partnership brings together the TMC with the Osong Medical Innovation Foundation, or KBIOHealth. The Biobridge aims to support the commercialization of Korean biotech and life science startups in the U.S., foster clinical research, and boost collaboration in the public, private and academic sectors.

Through the partnership, TMC will also develop a Global Innovators Launch Pad to foster U.S. market entry for international health care companies. Founders will be selected to participate in the 10-week program at the TMC Innovation Factory in Houston.

“Gene and cell therapies are driving biotech innovation, opening possibilities for treating diseases once thought untreatable," William McKeon, president and CEO of the Texas Medical Center, said in a news release. "Expanding biomanufacturing capacity is essential to delivering the next wave of these therapies, and partnerships with leading innovators will strengthen our efforts in Houston and internationally.”

McKeon officially signed the TMC Korea BioBridge Memorandum of Understanding with Myoung Su Lee, chairman of KBIOHealth, in South Korea in October.

"This collaboration marks a significant milestone for Korea’s biohealth ecosystem, creating a powerful bridge between Osong and Houston," Lee added in the release. "By combining KBIOHealth’s strength in research infrastructure and Korea’s biotech talent with TMC’s global network and accelerator platform, we aim to accelerate innovation and bring transformative solutions to patients worldwide.”

This is the seventh international strategic partnership for the TMC. It launched its first BioBridge with the Health Informatics Society of Australia in 2016. It launched its TMC Japan BioBridge, focused on advancing cancer treatments, last year. It also has BioBridge partnerships with the Netherlands, Ireland, Denmark and the United Kingdom.